Cancer of the Gastroesophageal Junction: Combined Modality Therapy

Surgical Oncology Clinics of North America

Volumn 15, Issue 4, 2006, Pages 803-824

  Ilson, David H ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CELECOXIB; CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; GEFITINIB; IRINOTECAN; MATUZUMAB; MITOMYCIN; MONOCLONAL ANTIBODY; PACLITAXEL; PANITUMUMAB; PLATINUM COMPLEX; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; VINBLASTINE;

BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGITIS; HUMAN; LOWER ESOPHAGUS SPHINCTER; LYMPH NODE METASTASIS; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NAUSEA; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; PROGNOSIS; REVIEW; UNITED STATES;

ADENOCARCINOMA; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGOGASTRIC JUNCTION; HUMANS; NEOADJUVANT THERAPY; STOMACH NEOPLASMS;

EID: 33749334161     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2006.07.011     Document Type: Review

References (81)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics 2005. CA Cancer J Clin 55 (2005) 10-30
2. Ferlay J., Bray F., and Pisani P. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide. Version 1.0. IARC Cancer Base No. 5 (2001), IARC Press, Geneva (Switzerland)
3. Devesa S.S., Blot W.J., and Fraumeni Jr. J.F. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83 (1998) 2049-2053
4. Lagergren J., Bergstrom R., Lindgren A., et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340 (1999) 825-831
5. Spechler J.S. Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans. The Department of Veterans Affairs Gastroesophageal Reflux Disease Study Group. N Engl J Med 326 (1992) 786-792
6. Engel L.S., Chow W., Vaughan T.L., et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 95 (2003) 1404-1413
7. Spechler J. Clinical practice. Barrett's esophagus. N Engl J Med 346 (2002) 836-842
8. Corley D.A., Kerlikowske K., Verma R., et al. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 124 (2003) 47-56
9. Siewert J.R., Feith M., and Stein H.J. Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification. J Surg Oncol 90 (2005) 139-146
10. Orringer M.B., Marshall B., and Iannettoni M.D. Transhiatal esophagectomy for treatment of benign and malignant esophageal disease. World J Surg 25 (2001) 196-203
11. Skinner D.B. En bloc resection for neoplasms of the esophagus and cardia. J Thorac Cardiovasc Surg 85 (1983) 59-71
12. Hulscher J.B.F., van Sandick J.W., de Boer A.G.E.M., et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 347 (2002) 1662-1669
13. Kelsen D.P., Ginsberg R., Pajak T.F., et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339 (1998) 1979-1984
14. Clark P.I. Medical research council randomized trial of surgery with or without pre-operative chemotherapy in resectable cancer of the oesophagus. Ann Oncol 11 Suppl 4 (2000)
15. Cunningham D., Allum W.H., Stenning S.P., et al. Perioperative chemotherapy versus surgery alone for respectable gastroesophageal cancer. N Engl J Med 355 1 (2006) 11-20
16. Ducreux M., Nordlinger B., Ychou M., et al. Resected Gastric Adenocarcinoma: Randomized Trial of Adjuvant Chemotherapy with 5 FU-Cisplatin (FUP) [abstract]. Final Results of the FFCD 8801 Trial. J Clin Oncol 19 (2000) 241
17. Bajetta E., Buzzoni R., Marinai L., et al. Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol 13 (2002) 299
18. Floriani M., Tinazzi A., Buda A., et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol 11 (2000) 837-843
19. Armanios M., Xu R., Forastiere A., et al. Adjuvant chemotherapy for resected adenocarcinoma of the esophagus, gastro-esophageal junction, and cardia: phase II trial (E8296) of the Eastern Cooperative Oncology Group. J Clin Oncol 22 (2004) 4495-4499
20. Herskovic A., Martz K., Al-Sarraf M., et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326 (1992) 1593-1598
21. Cooper J., Guo M.D., Herskovic A., et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 281 (1999) 1623-1627
22. Urba S.G., Orringer M.B., Turrisi A., et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19 2 (2001) 305-313
23. Walsh T.N., Noonan N., Hollywood D., et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335 (1996) 462-467
24. Bosset J.F., Gignoux M., Triboulet J.P., et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous cell cancer of the esophagus. New England radiotherapy for esophageal carcinoma. J Thorac Cardiovasc Surg 5 (1992) 887-895
25. Burmeister B., Walpole E., Burmeister E., et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 6 (2005) 659-668
26. Tepper J., Krasna M., Niedzwicki D., et al. Superiority of trimodality therapy to surgery alone in esophageal cancer: results of CALGB 9781. J Clin Oncol 24 (2006) 181
27. Kaklamanos I., Walker G., Ferry K., et al. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Sur Oncol 10 (2003) 754-761
28. Macdonald J., Smalley S., Benedetti J., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345 (2001) 725-730
29. Coia L.R., John M.J., Haller D.G., et al. The evaluation and treatment of patients receiving radiation therapy for carcinoma of the esophagus: results of the 1992-1994 Patterns of Care Study. Cancer 85 12 (1999) 2499-2505
30. Bedenne L, Michel P, Bouche O, et al. Randomized phase III trial in locally advanced esophageal cancer: radiochemotherapy followed by surgery versus radiochemotherapy alone (FFCD 9102). Presented at the Am Soc Clin Oncol Orlando 2002.
31. Stahl M., Stuschke M., and Lehmann N. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23 10 (2005) 2310-2317
32. Swisher S., Wynn P., Putnam J., et al. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg 123 (2002) 175-183
33. Minsky B.D., Neuberg D., Kelsen D.P., et al. Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12): phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 43 (1999) 517-523
34. Minsky B.D., Pajak T.F., Ginsberg R.J., et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 20 5 (2002) 1167-1174
35. Gaspar L.E., Winter K., Kocha W.I., et al. Phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (radiation therapy oncology group study 9207): final report. Cancer 88 (2000) 988-995
36. Bains M., Minsky B., Rusch V., et al. A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: initial results. J Thorac Cardiovasc Surg 124 (2002) 270-277
37. Weber W., Becker K., Dittler H.J., et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19 (2001) 3058-3065
38. Adelstein D., Rice T.W., Rybicki L.A., et al. Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. J Clin Oncol 18 (2000) 2032-2039
39. Blanke C.D., Choy H., Teng M., et al. Concurrent paclitaxel and thoracic irradiation for locally advanced esophageal cancer. Semin Radiat Oncol 9 (1999) 43-52
40. Urba S., Orringer M., Iannettoni M., et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 98 10 (2003) 2177-2183
41. Wright C.D., Wain J.C., Lynch T.J., et al. Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study. J Thorac Cardiovasc Surg 114 (1997) 811-815
42. Weiner L., Colarusso P., Goldberg M., et al. Combined-modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy. Semin Oncol 24 6 Suppl 19 (1997) 93-95
43. Meluch A.A., Hainsworth J.D., Gray J.R., et al. Preoperative combined modality therapy with paclitaxel, carboplatin, prolonged infusion 5-fluorouracil, and radiation therapy in localized esophageal cancer: preliminary results of a Minnie Pearl Cancer Research Network phase II trial. Cancer J Sci Am 5 (1999) 84-91
44. Roof K.S., Coen J., Lynch T.J., et al. Neo adjuvant radiation, cisplatin 5-FU, +/- paclitaxel in locally advanced esophageal cancer. [abstract]. J Clin Oncol 23 (2004) 323
45. Brenner B., Ilson D., Minsky B., et al. Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. J Clin Oncol 22 (2004) 45-52
46. Safran H., Gaissert H., Akerman P., et al. Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Cancer Invest 19 (2001) 1-7
47. Ajani J.A., Walsh G.L., Komaki R., et al. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer 100 (2004) 2347-2354
48. Mauer A.M., Haraf D.C., Ferguson M.K., et al. Docetaxel-based combined modality therapy for locally advanced carcinoma of the esophagus and gastric cardia. [abstract]. J Clin Oncol 19 (2000) 246
49. Ilson D., Bains M., Kelsen D., et al. Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. J Clin Oncol 21 (2003) 2926-2932
50. Enzinger P, Mamon H, Choi N, et al. Phase II cisplatin, irinotecan, celecoxib and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer [abstract]. Proc of the Gastrointestinal Symposium of the American Society of Clinical Oncology 2005, Hollywood (FL), January 27-29, 2005.
51. Sarbia M.S.M., Fink U., Willers R., et al. Expression of apoptosis-regulating proteins and outcome of esophageal cancer patients treated by combined therapy modalities. Clin Cancer Res 4 (1998) 2991-2997
52. Kishi K.D.Y., Miyata H., Yano M., et al. Prediction of the response to chemoradiation and prognosis in oesophageal squamous cancer. Br J Surg 89 (2002) 597-603
53. Downey R.J., Ilson D., Ginsberg R., et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 21 (2003) 428-432
54. Flamen P., Van Cutsem E., Lerut A., et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 13 (2002) 361-368
55. Gibson M.K., Abraham S.C., Wu T.T., et al. Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res 9 17 (2003) 6461-6468
56. Walsh T.N., Grannell M., and Mansoor S. Predictive factors for success of neo-adjuvant therapy in upper gastrointestinal cancer. J Gastroenterol Hepatol 17 Supp 1 (2002) S172-S175
57. Harpole Jr. D.H., Moore M.D., Hemdon J.E., et al. The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 7 3 (2001) 562-569
58. Ribeiro Jr. U., Finkelstein S.D., Safatle-Ribeiro S.E., et al. p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer 83 1 (1998) 7-18
59. Kanamoto A., Kato H., Tochimori Y., et al. No prognostic significance of p53 expression in esophageal squamous cell carcinoma. J Surg Oncol 72 2 (1999) 94-98
60. Hickey K., Grehan D., Reid I.M., et al. Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy. Cancer 74 6 (1994) 1693-1698
61. Nicholson R.I., Gee J.M., and Harper M.E. EGFR and cancer prognosis. Eur J Cancer 37 Suppl 4 (2001) S9-S15
62. Hirai T., Kuwahara M., Yoshida K., et al. Clinical results of transhiatal esophagectomy for carcinoma of the lower thoracic esophagus according to biological markers. Dis Esophagus 11 4 (1998) 221-225
63. Itakura Y., Sasano H., Shiga C., et al. Epidermal growth factor receptor over-expression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 74 3 (1994) 795-804
64. Kitagawa Y., Ueda M., Ando N., et al. Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma. Clin Cancer Res 2 5 (1996) 909-914
65. Ito T., Kaneko K., Makino R., et al. Prognostic value of p53 mutations in patients with locally advanced esophageal carcinoma treated with definitive chemoradiotherapy. J Gastroenterol 36 5 (2001) 303-311
66. al-Kasspooles M., Moore J.H., Orringer M.B., et al. Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int J Cancer 54 2 (1993) 213-219
67. Wilkinson N.W., Black J.D., Roukhadze E., et al. Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. J Gastrointest Surg 8 4 (2004) 448-453
68. Sunpaweravong P., Sunpaweravong S., Puttawibul P., et al. Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 131 2 (2005) 111-119
69. Herbst R.S., Fukuoka M., and Baselga J. Gefitinib-a novel targeted approach to treating cancer. Nat Rev Cancer 4 12 (2004) 956-965
70. Dragovich T, McCoy S, Urba S, et al. SWOG 0127: phase II trial of erlotinib in GEJ and gastric adenocarcinoma [abstract]. 2005 Gastrointestinal Cancers Symposium ASCO, Hollywood (FL), January 27-29, 2005.
71. Tew W, Shah M, Schwartz G, et al. Phase II trial of erlotinib for second line treatment in advanced esophageal cancer [abstract]. 2005 Gastrointestinal Cancers Symposium ASCO, Hollywood (FL), January 27-29, 2005.
72. Perez-Soler R. HER1/EGFR targeting: refining the strategy. Oncologist 9 1 (2004) 58-67
73. Safran H., Deptrillo T., Nadeem A., et al. Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study. Cancer Invest 22 5 (2004) 670-677
74. Ferrara N., and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 18 1 (1997) 4-25
75. Chen H.X. Expanding the clinical development of bevacizumab. Oncologist 9 Suppl 1 (2004) 27-35
76. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 23 (2004) 2335-2342
77. Shih C.H., Ozawa S., Ando N., et al. Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res 6 3 (2000) 1161-1168
78. Kitadai Y., Haruma K., Tokutomi T., et al. Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin Cancer Res 4 9 (1998) 2195-2200
79. Inoue K., Ozeki Y., Suganuma T., et al. Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression. Cancer 79 2 (1997) 206-213
80. Kleespies A., Guba M., Jauch K.W., et al. Vascular endothelial growth factor in esophageal cancer. J Surg Oncol 87 2 (2004) 95-104
81. Govindan R., Fineberg R., McLeod H., et al. A phase II study of cisplatin, 5 fluorouracil (5-FU), radiation (RT) and celecoxib in patients with resectable esophageal cancer (EC): updated results from the Hoosier Oncology Group (HOG) study. [abstract]. J Clin Oncol 23 (2004) 325